What is Velasof and what is it used for? Velasof (generic Epclusa) is a generic antiviral drug produced by Hetero that is used to treat chronic hepatitis C in adults. Velasof contains the active substances sofosbuvir and velpatasvir. How is Velasof used? Velasof can only be obtained with a prescription and treatment should be initiated and supervised by a physician experienced in the management of patients with chronic hepatitis C. Velasof is available as tablets containing 400 mg of sofosbuvir and 100 mg of velpatasvir. Hepatitis C virus exists in several varieties (genotypes), and Velasof can be used to treat hepatitis C caused by all genotypes of the virus.
The recommended dose is one tablet taken once a day for 12 weeks. In patients with decompensated liver disease (when the liver is no longer functioning properly), Velasof is taken together with another medicine, called ribavirin. Addition of ribavirin to Velasof treatment may also be considered in patients with compensated liver cirrhosis (liver sclerosis but with proper functioning) and who are infected with hepatitis C virus genotype 3, which is harder to treat. How ac tert state the Velasof? Velasof active substances, sofosbuvir and velpatasvirul, blocking two proteins essential for replication of hepatitis C virus sofosbuvir block the action of an enzyme called "NS5B RNA-dependent RNA polymerase" and velpatasvirul targets a protein called "NS5A".
Blocking these proteins, Velasof stops multiplication of hepatitis C virus infection of new cells. What is the risk associated with Velasof? Velasof is contraindicated in combination with the following drugs, as they can reduce and velpatasvir sofosbuvir concentrations in the blood, and therefore can reduce the effectiveness of Velasof: - rifampicin, rifabutin (antibiotics); - carbamazepine, phenobarbital, phenytoin (medicines to treat epilepsy); - St John's wort (herbal tea used to treat depression and anxiety). For the full list of side effects or restrictions with Velasof, read the prospectus. The product summary and the package leaflet included recommendations and precautions for the safe and effective use of Velasof, to be followed by healthcare professionals and patients.